Cemiplimab

Therapeutic indications

Cemiplimab is indicated for:

Metastatic or locally advanced cutaneous squamous cell carcinoma

Population group: only adults (18 years old or older)

Cemiplimab as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Locally advanced or metastatic basal cell carcinoma

Population group: only adults (18 years old or older)

Cemiplimab as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Non-small cell lung cancer with PD-L1 ≥50%

Population group: only adults (18 years old or older)

Cemiplimab as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:

  • locally advanced NSCLC who are not candidates for definitive chemoradiation, or
  • metastatic NSCLC.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Non-small cell lung cancer with PD-L1 ≥50%

Population group: only adults (18 years old or older)

Cemiplimab in combination with platinum-based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:

  • locally advanced NSCLC who are not candidates for definitive chemoradiation, or
  • metastatic NSCLC.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Cervical cancer

Population group: women, only adults (18 years old or older)

Cemiplimab as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Cemiplimab is contraindicated in the following cases:

Lactation

Lactation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2024: LIBTAYO Concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈